University of Guelph.
J Atten Disord. 2010 Jan;13(4):414-9. doi: 10.1177/1087054708326269.
In this small pilot study, the association of comorbid anxiety with the treatment of ADHD is studied.
Eighteen volunteers from a pediatric clinic are tested for ADHD and anxiety and assessed for behavioral and cognitive ADHD symptomology. Response to methylphenidate as treatment for ADHD symptoms is measured 2 to 3 weeks, and again 4 to 6 weeks following the diagnosis of ADHD.
Methylphenidate proves effective for treating ADHD symptoms (both behavioral and cognitive). Participants are categorized into two groups, those with ADHD and comorbid anxiety and those with ADHD alone. Behaviorally, no statistically significant differences are seen in response between the two groups; however; cognitively, the non-anxious group improves significantly more than the anxious group.
Although anxiety may not affect behavioral response to stimulant medication in ADHD, it does appear to affect the medication response of more subtle symptoms of cognitive performance in ADHD patients.
在这项小型试点研究中，研究了共病焦虑症与 ADHD 治疗的关联。
从儿科诊所招募了 18 名志愿者进行 ADHD 和焦虑症测试，并评估其 ADHD 的行为和认知症状。在 ADHD 诊断后 2 至 3 周和 4 至 6 周，评估使用哌醋甲酯治疗 ADHD 症状的效果。
哌醋甲酯对治疗 ADHD 症状（行为和认知）有效。参与者分为两组，一组为 ADHD 合并焦虑症，另一组为单纯 ADHD。在行为方面，两组之间的反应没有统计学上的显著差异；然而，在认知方面，不焦虑组的改善明显大于焦虑组。
尽管焦虑症可能不会影响 ADHD 患者对兴奋剂药物的行为反应，但它似乎确实会影响 ADHD 患者认知表现等更微妙症状对药物的反应。
